NCT05712876View on ClinicalTrials.gov

A Phase 1 Study to Investigate Safety, Tolerability, and Pharmacokinetics of CK-0045 in Healthy Participants and Otherwise Healthy Participants With Obesity

PHASE1CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

December 26, 2022

Primary Completion Date

January 4, 2024

Study Completion Date

January 4, 2024

Conditions
Healthy
Interventions
DRUG

CK-0045

Interleukin-22 agonist

DRUG

Placebo

Matching placebo

Trial Locations (1)

2650

SGS Clinical Research, Clinical Pharmacology Unit, Edegem

Sponsors

Lead Sponsor

Cytoki Pharma
All Listed Sponsors
collaborator

SGS Life Sciences, a division of SGS Belgium NV

OTHER

lead

Cytoki Pharma

INDUSTRY